由于酵母重组乙型肝炎(HB)疫苗近来已获准使用,疫苗的开发已进入新时代。该疫苗将与血源性HB疫苗进行竞争,后者是用慢性HB感染者血浆制备的唯一正式产品。几项随机、双盲的安慰剂对照试验清楚地表明,血源疫苗在预防高危人群HB方面非常有效。血源疫苗于1981年得到批准,1982年7月普及使用后不久,在男性同性恋者中发现AI Vaccine development has entered a new era as yeast recombinant hepatitis B (HB) vaccine has recently been approved for use. The vaccine will compete with the blood-borne HB vaccine, the only formal product made from the plasma of chronically infected HBs. Several randomized, double-blind, placebo-controlled trials have clearly demonstrated that blood-borne vaccines are very effective in preventing HB in high-risk groups. The blood-borne vaccine was approved in 1981, and shortly after its widespread use in July 1982, it was found in male homosexuals that AI